Emgality 300 mg: An FDA-approved treatment and dose specifically for your patients with episodic cluster headache1



Recommended dosing with no titration required1a

One dose of Emgality 300 mg equals three 100 mg doses

300 mg administered as 3 consecutive subcutaneous (SC) injections of 100 mg each, at the onset of the cluster period, and then monthly until the end of the cluster period.

  • 300 mg dose; this comes in 3 x 100 mg prefilled syringes
  • These 3 syringes are administered subcutaneously, one after another
  • Patients begin treatment at the onset of a cluster period
  • Patients take this 300 mg dose every month until their cluster period ends

Please review full Instructions for Use with your patients.

aThe Emgality prefilled syringe needle is 27 gauge x 1/2 inch.3

Hypothetical dosing example1

A patient with cluster periods lasting 7 weeks

Chart explaining dosing from onset of cluster period, one month after onset, and the end of the cluster period


Consider having patients fill their prescription for their upcoming cluster cycle while they are in remission.

Advise patients to1,4:

  • Store product refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect it from light until use
  • Check expiration date on product prior to use

SELECT IMPORTANT SAFETY INFORMATION
Contraindication

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


Reference: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0085. 3. Data on File. Lilly USA, LLC. DOF-GZ-US-0071. 4. Emgality [Instructions for Use]. Indianapolis, IN: Lilly USA, LLC.

Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 10DEC2019